Analyst Research Report Snapshot


Aurobindo Pharma Ltd. | Q1FY14 Result / Concall Update




IndiaNivesh Securities Pvt Ltd


13 Aug 2013





Companies referenced:


Available for Immediate Download

Aurobindo Pharma Ltd. Q1FY14 Result / Concall Update At CMP of Rs 187, the stock is trading at P/E multiple of 6.8x of FY14E & 5.9x of FY15E earnings estimates. We adjusted margins estimates by assuming higher contribution from the formulations & lower other expense linked with operating leverage to come in play going forward. We maintain BUY rating on the stock with the target price of Rs 242 (which translates to P/E multiple of 7.6x of FY15E).

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.